8 Drugs Approved for Primary Care: Q1 2026

In the first quarter of 2026, the US Food and Drug Administration (FDA) issued a series of regulatory decisions spanning endocrinology, dermatology, obesity management, rare diseases, and men’s health. These approvals reflect continued momentum in both chronic disease management and novel therapeutic delivery approaches, with several first-in-class or first-in-category products entering the market.